8-K: TScan Therapeutics Unveils Promising Heme Malignancy Data

TScan Therapeutics presented promising clinical data for its TSC-101 therapy in hematologic malignancies and outlined strategic plans for its solid tumor and autoimmunity programs at the J.P. Morgan Healthcare Conference.

Summary

• TScan Therapeutics made available a corporate presentation on January 12, 2026, for potential meetings at the 44th Annual J.P. Morgan Healthcare Conference.
• The company is a fully integrated, next-generation TCR-T cell therapy company with programs in hematologic malignancies, solid tumors, and autoimmunity.
• For the Heme Malignancy Program, TSC-101 showed promising data in preventing relapse post-bone marrow transplant, with favorable Relapse-Free Survival (RFS) and Overall Survival (OS) compared to the control arm, and no Dose Limiting Toxicities (DLTs).
• 100% (3/3) of patients treated with TSC-101 were relapse-free 2-years post-HCT, showing detectable TSC-101 cells and no evidence of disease (as of Sept 19, 2025 data cut).
• The company expects to launch a pivotal study for TSC-101 in Q2 2026, having reached agreement with the FDA on the pivotal trial design, which will mirror the ALLOHA Phase 1 trial.
• TSC-101 is projected to generate over $1 billion annually at peak penetration in the U.S., targeting 2,100 addressable U.S. patients at launch.
• TScan plans to file two Investigational New Drug (IND) applications for TSC-102 (A*03:01 and A*01:01) in Q1 2026 to expand the addressable market.
• The Solid Tumor Program is developing in vivo-engineered multiplex TCR-T cell therapies, with clinical and preclinical data expected in H1 2026.
• The Autoimmunity Program has identified novel autoantigens for systemic sclerosis, ulcerative colitis, ankylosing spondylitis, and birdshot uveitis, and has an ongoing collaboration with Amgen for Crohn's disease target discovery.
• As of September 30, 2025, TScan Therapeutics had $184.5 million in cash and cash equivalents, which is expected to fund operations into H2 2027.
• Total economic shares outstanding were 129.8 million as of September 30, 2025, including 56,747,993 common shares and 73,087,945 pre-funded warrants.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for TSC-101, a clear regulatory path with FDA agreement, a robust financial runway, and strategic expansion plans across multiple therapeutic areas. While early-stage data and non-statistical significance are noted, the overall outlook and progress are highly favorable for a biotech company at this stage.

Positives

• Promising clinical data for TSC-101 in hematologic malignancies, demonstrating favorable Relapse-Free Survival (RFS) and Overall Survival (OS) with no Dose Limiting Toxicities (DLTs).
• 100% (3/3) of TSC-101 subjects remained relapse-free at 2 years post-HCT, showing detectable TSC-101 cells and no evidence of disease, indicating durable responses.
• Agreement reached with the FDA on the pivotal trial design for TSC-101, providing a clear regulatory pathway for market entry.
• TSC-101 is projected to have a substantial commercial opportunity, with potential peak annual revenue exceeding $1 billion in the U.S. alone.
• Expansion opportunities for the heme program are planned with two additional IND filings for TSC-102 (A*03:01 and A*01:01) in Q1 2026, broadening the addressable patient population globally.
• A strong cash position of $184.5 million as of September 30, 2025, provides a financial runway into H2 2027.
• Significant progress in the solid tumor program, with first patients treated with multiplex TCR-T therapy and ongoing development of an in vivo engineering platform.
• Successful identification of novel autoantigens in the autoimmunity program and an ongoing collaboration with Amgen for target discovery in Crohn's disease.
• The commercial-ready manufacturing process for TSC-101 reduces manufacturing time by 5 days (from 17 to 12 days) and significantly reduces ex vivo expansion (from a mean of 13-fold to 4-fold), with all runs to date being successful and meeting target dose.

Negatives

• Hazard ratios for RFS (0.50) and OS (0.61) for TSC-101, while favorable, have p-values of 0.23 and 0.52 respectively, indicating that the observed differences are not yet statistically significant in the current small dataset.
• The control group for TSC-101 showed only 1 of 4 (25%) subjects remaining relapse-free at 2 years, highlighting the high unmet need but also the limited size of the control cohort.
• The solid tumor and autoimmunity programs are in earlier stages of development, with clinical and preclinical data for solid tumors expected in H1 2026 and autoimmunity programs primarily in discovery/preclinical phases.

Risks

• The beneficial characteristics, safety, efficacy, therapeutic effects, and potential advantages of TScan's TCR-T therapy candidates may not be realized.
• TScan's expectations regarding its preclinical studies being predictive of clinical trial results may not hold true.
• Uncertainty regarding the timing of the initiation, progress, and expected results of TScan's preclinical studies, clinical trials, and research and development programs.
• Risks related to TScan's plans for developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy.
• Estimates of the size of the addressable market for TScan's TCR-T therapy candidates may be inaccurate.
• Challenges related to TScan's manufacturing capabilities and the scalable nature of its manufacturing process.
• Estimates regarding expenses, future milestone payments and revenue, capital requirements, and needs for additional financing may be incorrect.
• TScan's expectations regarding competition may not be accurate.
• Risks related to TScan's anticipated growth strategies.
• Ability to attract or retain key personnel.
• Ability to establish and maintain development partnerships and collaborations.
• TScan's expectations regarding federal, state, and foreign regulatory requirements.
• Ability to obtain and maintain intellectual property protection for its proprietary platform technology and product candidates.
• Sufficiency of TScan's existing capital resources to fund its future operating expenses and capital expenditure requirements.
• Other factors described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of TScan's most recent Annual Report on Form 10-K and any other filings with the SEC.

Future Outlook

TScan Therapeutics anticipates a transformational year in 2026, with the launch of the pivotal study for TSC-101 in Q2, filing of two INDs for TSC-102 in Q1, and expected clinical and preclinical data from the solid tumor program in H1. The company aims to expand its addressable market for heme malignancies and advance its in vivo-engineered multiplex TCR-T therapies for solid tumors, while continuing to identify novel autoantigens in its autoimmunity program. Existing cash is expected to fund operations into H2 2027.

Management Comments

• 2026 will be a transformational year for TScan.

Industry Context

TScan Therapeutics operates in the highly competitive and rapidly evolving field of cell therapy, specifically TCR-T cell therapy. Its focus on targeting residual disease in hematologic malignancies addresses a critical unmet need post-allogeneic HCT, where relapse rates are high. The development of multiplex TCR-T therapies and in vivo engineering for solid tumors aligns with the industry trend of overcoming tumor heterogeneity and improving the accessibility and scalability of cell therapies. The autoimmunity program leverages a proprietary platform for target discovery, positioning TScan in the growing area of precision medicine for autoimmune diseases, moving beyond general immune suppression. The collaboration with Amgen underscores the industry's interest in novel target identification for complex diseases like Crohn's.

Comparison to Industry Standards

• TSC-101's favorable pricing corridor is established in the range of recent cell therapy approvals, indicating competitive positioning.
• The commercial-ready manufacturing process reduces manufacturing time by 5 days (from 17 to 12 days) and significantly reduces ex vivo expansion (from a mean of 13-fold to 4-fold), which could be a competitive advantage in terms of cost and speed compared to other autologous cell therapies.
• The in vivo lentiviral approach for solid tumors aims to solve key challenges of autologous TCR-T, such as eliminating the need for lymphodepletion, patient-specific manufacturing (off-the-shelf), and vein-to-vein time, which are common hurdles for current CAR-T and TCR-T therapies.
• The company targets approximately 40 authorized treatment centers at launch, covering approximately 60% of all allo transplants in the U.S., which is a focused and efficient market access strategy for a specialized therapy.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, clear regulatory path, strong financial position, and potential for significant market penetration and revenue.
• Patients (AML/MDS): Potential for a new, effective therapy (TSC-101) to prevent relapse after allogeneic HCT, addressing a high unmet medical need.
• Employees: Continued stability and growth opportunities due to ongoing R&D and commercialization efforts.
• Healthcare Providers/Transplant Centers: Introduction of a new therapeutic option (TSC-101) that integrates with current standard of care, potentially improving patient outcomes.
• Regulators (FDA): Engagement and agreement on pivotal trial design indicate a constructive relationship and progress towards regulatory approval.

Next Steps

• File two INDs for TSC-102 (A*03:01 and A*01:01) in Q1 2026.
• Launch pivotal study for TSC-101 in Q2 2026.
• Present clinical and preclinical data on solid tumor program in H1 2026.
• Continue follow-up for TSC-101 patients to gather more two-year relapse data.
• Continue developing in vivo-engineered multiplex TCR-T cell therapies for solid tumors.
• Continue target discovery in autoimmunity, including collaboration with Amgen.
• Further develop go-to-market strategy for TSC-101, including payer reimbursement pathways and ATC engagement.

Key Dates

Recommendation

The filing provides compelling evidence of TSC-101's efficacy and safety in a high-risk patient population, with 100% relapse-free survival at 2 years in the initial cohort. The FDA's agreement on the pivotal trial design significantly de-risks the regulatory pathway. With a projected peak revenue exceeding $1 billion in the U.S. alone and a cash runway into H2 2027, the company is well-positioned for substantial growth. The progress in solid tumors and autoimmunity further adds to the long-term value proposition. This combination of strong clinical data, regulatory clarity, and financial stability makes TScan Therapeutics a highly attractive investment.

Keywords

TCR-T cell therapy, hematologic malignancies, AML, MDS, solid tumors, autoimmunity, TSC-101, TSC-102, J.P. Morgan Healthcare Conference, clinical trials, FDA agreement, relapse prevention, allogeneic HCT, ImmunoBank, in vivo engineering, TargetScan platform, biotechnology, oncology, immunotherapy